| Disease |
Platform |
Product name |
Biomarker |
Significant finding |
Sample type |
Sampel size |
Reference |
| Ovarian Cancer |
Glass slides-label based antibody array |
RayBiotech L-507 |
Screening marker |
Five proteins, including IL-2 receptor alpha, endothelin, osteprotegerin, vascular endothelial growth factor D (VEGF-D) and betacellulin (BTC) were identified to distinguish ovarian cancer from healthy controls. |
Serum |
serum samples from 47 patients with ovarian cancers, 33 patients with benign ovarian masses and 39 healthy, age-matched controls |
(15) |
| Breast Cancer |
Nitrocellulose membranes-sandwitch-based antibody array |
RayBiotech Human Cytokine Array III C-series |
pre-clinical studies |
4 4 biomarkers were identified with increased expression in MCF-7/Her2-18 cells (CXCL8, IL8, CXCL1, and GRO) |
Cultural Media |
Her-2 overexpressed cell line MCF-7/Her2-18 and parental cell line MCF-7/neo cell line |
(27) |
| Breast Cancer |
Glass slides-label-based antibody array |
In house custom production |
efficacy markers |
A panel of 4 proteins (AP-2, catalase, thymidylate synthase, and ErbB2) was higher in MDA-MB-231 cells compared with control cells |
Cell Lysates |
THP cell line exposed to different drug delivery systems, including amphotericin B (AMB), Fungizone (FZ) and Amphotec (ABCD),and controls AmBisome (L-AMB) or Abelcet (ABLC) |
(25) |
| Breast Cancer |
Glass slides-label-based antibody array |
The BD antibody microarray 380 |
pre-clinical studies |
A panel of protein markers were identified to distinguish malignant and adjacent normal breast tissue in a patient with primary breast cancer, including casein kinase Ie, p53, annexin XI, CDC25C, eIF-4E and MAP kinase 7 and 14-3-3e. |
Tissue Lysates |
Normal and malignant breast tissue was obtained from a 54-year-old consenting post-menopausal patient undergoing modified mastectomy for early breast cancer |
(24) |
| Breast Cancer |
Glass slides-label-based antibody array |
In house custom production |
Prognosis marker |
A panel of 21 protein markers were identified to distingusih high-vs-low-risk groups for development of distant metastatic breast cancers |
Serum |
240 sera samples from 64 primary breast cancer patients, which were collected at the primary operation and then 3-6 month later |
(29) |
| Brain Tumor |
Glass slides-label-based antibody array |
In house custom production |
Prognosis marker |
A 15-marker panel was identified to classification of GBM patients into long-term survival vs short-term survival group |
Serum |
serum samples from 18 GM patients and 17 healthy controls |
(32) |
| Colorectal Cancer( CRC ) |
Glass slides-label-based antibody array |
RayBiotech L-507 |
treatment monitoring marker |
58 and 47 proteins identified with significant modulation at post vaccination of month 2 and 4, compared with prevaccination |
plasma |
14 samples from 18 patients with prevaccination, post vaccination month 2 and month 4 |
(31) |
| Prostate Cancer |
Nitrocellulose membranes-sandwitch-based antibody array |
RayBiotech Human Cytokine ArrayC-series 2000 |
pre-clinical studies |
MCP-1 and IL-8 was highly expressed in all prostate cancer cell lines compared with control cell line. In addition, Levels of GRO-alpha were greater in LNCaP, C4-2B and PC3 cells compared with PrEC cells, Levels of VEGF, CXCL-16 and MMP-9 were greater in PC3 cells compared with PrEC cells |
Cultural Media |
4 different prosate cancer cell lines ( LNCaP, C4-2B, PC3, A549) and prostate cell line PrEC. |
(30) |
| Bladder Cancer |
Glass slides-RCA antibody array |
In house custom production |
screening marker |
Serum protein profiles measured by an antibody array containing 254 antibodies discriminated bladder cancer patients from controls (n _ 95) with a correct classification rate of 93.7%. A second independent antibody array containing 144 antibodies revealed that protein profiles provide predictive information by stratifying patients with bladder tumors (n _ 37) based on their overall survival (P<0.05) |
Serum |
SerumSerum samples from 95 individuals representing 58 controls and 37 patients with bladder cancer |
(34) |
| Pancreatic Cancer |
Glass slides-RCA antibody array |
In house custom production |
screening marker |
|
Serum |
One hundred forty-two serum samples were used from three classes: healthy subjects (n = 50), pancreatic adenocarcinoma patients (n = 61), and patients with benign pancreatic diseases (n = 31) |
(37) |
| Pancreatic Cancer |
Glass slides-label-based antibody array |
In house custom production |
screening and prognosis marker |
|
Serum |
serum samples from 24 pancreatic cancer patients and 20 healthy controls |
(33) |
| Leaukemia |
Nitrocellulose membranes-sandwitch-based antibody array |
RayBiotech Human Cytokine Array |
efficacy markers |
|
Culture Media |
THP cell line exposed to different drug delivery systems, including amphotericin B (AMB), Fungizone (FZ) and Amphotec (ABCD),and controls AmBisome (L-AMB) or Abelcet (ABLC) |
(36) |
